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Abstract 
Gut microbiota are the primary focus for a number of active research fields; 
one of their main areas of effect seem to be their effects on acute pain. 
Though it is generally realized that development of gut microbiota is after 
birth, the initial microbial core originates from maternal microbiota in fetus 
life, rapidly colonizing to adulthood microflora in 3-5 years. Understanding 
the crosstalk between microbiota, changes in gut flora and post-operative 
pain, and recognizing the underlying mechanisms are novel fields of study. 
 
 
Keywords: Gut microbiota; pain; cellular and molecular mechanisms 
 
 
Please cite this article as: Alipoor E, Shadnoush M, Dabbagh A. Acute post-operative 
pain and gut microbiota; is there any (clinical) relationship?. J Cell Mol Anesth. 





The body microorganisms, which are also 
called microbiota, lied mainly in the gut, other 
mucous membranes and skin. It is generally believed 
that microbiota develops after birth. However, the 
initial microbial core originates from maternal 
microbiota in fetus life, and the gut colonized rapidly 
to adulthood microflora within the first 3-5 years (1). 
The physiological functions of microbiota include 
defense against pathogens, providing nutrients such as 
vitamin B12, folate, and vitamin K, and modulating 
gut integrity and permeability, which could 
consequently affect the function of the immune 
system (2).  
The fermentation of indigestible carbohydrates 
by bacteria in the colon produces rapidly absorbed 
short chain fatty acids (SCFAs). SCFAs play an 
important role in the modulation of gene expression, 
cellular differentiation, proliferation and apoptosis, 
metabolism of lipids and glucose in liver, and 
regulation of different immune cells and 
inflammatory responses (3, 4). SCFAs bind to a 
member of G-protein-coupled receptors, GPR43. 
Experimental models of colitis, arthritis and asthma 
showed that both GPR43-deficient and germ-free 
mice manifested intensified or unresolving 
inflammation (5). The production of SCFAs in 
healthy people depends on dietary factors and 
substrate availability, intestinal transit time, and 
microbiota composition and species (6). Some 
bacteria could produce neuroactive substances 
including gamma-aminobutyric acid (GABA), 
serotonin, catecholamines, histamine, and 
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acetylcholine. These metabolites not only could affect 
neurophysiology of brain development and behavior, 
but could also regulate gastrointestinal, cardiac, 
respiratory, and endocrine functions through direct 
interaction with gastrointestinal receptors or entering 
into the circulation (7, 8). 
The effects of gut microbiota could partly 
occur through small non-coding RNA molecules 
called microRNAs. It has been demonstrated that 
microRNAs could modulate host gene expression and 
gut flora could reciprocally affect host microRNA 
expression (9). Moreover, fecal microRNAs could 
modulate gut flora by targeting bacterial gene 
expression and growth (10). MicroRNAs are major 
contributors of the immune system and also, a number 
of disease states; including the clinical conditions in 
the perioperative period (11, 12). The regulation of 
microRNAs by microbiota could affect intestinal 
epithelium and play an important role in the 
pathogenesis of disorders like inflammatory bowel 
disease (13). 
Despite relatively stable microbiota during life, 
different illnesses, surgeries, medications, dietary 
factors, and lifestyle changes could contribute to the 
imbalance of body microorganisms, or dysbiosis, and 
many gastrointestinal and extra-gastrointestinal 
disorders (1). For example, clinical and experimental 
studies showed that gut microbiota change in obesity. 
An increase in the Firmicutes and decrease in the 
Bacteroidetes, two dominant bacterial divisions have 
been reported in obese state (14, 15). These 
alterations could be associated with changes in the 
metabolic function of microbiota including higher 
capacity to absorb energy of nutrients (15). In 
addition, it has been shown that intestinal microbiota 
is considerably different in children with typical 
western diets rich in fat and sugar compared to those 
in rural communities consuming foods rich in fiber. 
There was a higher richness and biodiversity in 
microbiota, but reduced pathogenic strains with high 
fiber diets (16). Dietary fats, especially the saturated 
types, can change the composition of bile acids and 
gut flora, which in turn can cause dysbiosis and affect 
the immune function of the host (17). Stress could 
also substantially affect gut physiology and 
microbiota through reducing the beneficial 
Lactobacillus strain and increase pathogens like E. 
coli (18). Antimicrobial therapies affect the 
abundance and function of gut microbiota, which may 
lead to long-term dysbiosis and consequent disorders 
(19). 
The role of gut microbiota in the perioperative 
period diseases 
Previous studies have mainly focused on the 
role of microbiome diversity and abundance in 
chronic disorders including obesity, diabetes, 
intestinal disorders such as inflammatory bowel 
disease, irritable bowel syndrome (IBS), and 
colorectal cancer. The role of gut flora, and especially 
probiotics, has been considered recently in critical 
care. Probiotic refers to live nonpathogenic 
microorganisms, most commonly Lactobacillus and 
Bifidobacterium, that their sufficient amounts exert 
many health benefits through recovery of gut 
microbial balance (20). During critical illness, many 
factors could disturb the normal physiologic gut 
microbiota. The trauma or disease induced stress, 
along with medications like antibiotics, 
catecholamines and histamine H2 receptor blockers, 
and other supportive treatments such as artificial 
respiration might be involved (21). Remarkable 
alterations in the gut flora are also seen in digestive 
surgeries due to bowel cleansing (22). Many surgeries 
are accompanied with pre- and post- fasting state as a 
part of treatment or insufficient nutrition support. The 
direct effects of starvation on gut microbiota in 
critical conditions are not still well described. 
However, it has been observed that undernutrition in 
children and anorexia nervosa in young adults are 
associated with substantial changes in bacterial 
diversity and abundance (23, 24).  
Gut microbiota and pain (acute and chronic) 
The clinical effects of interventions on 
microbiota have been assessed in different types of 
major abdominal surgeries including liver 
transplantation, hepatectomy, and other organ 
resections. These studies mainly evaluated outcomes 
including immune function and infectious 
complication, antibiotic-associated diarrhea, epithelial 
permeability, duration of antibiotics use, and duration 
of hospital stay (21, 25).  
Post-operative pain is one of the most 
important complications in surgical patients. Few data 
is available on the relationship of this kind of acute 
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pain with gut microbiota and the effect of relevant 
interventions. However, the effect of gut microbiota 
as a key regulator of visceral pain has been stated 
recently. Visceral pain is referred to pain from 
internal organs such as abdomen, thorax or pelvis and 
is most prevalent in functional gastrointestinal 
disorders (26). Many animal studies have confirmed 
the involvement of gut microbiota on visceral pain. 
For example, it has been reported that germ-free mice 
showed visceral hypersensitivity. Besides, an 
increased gene expression of Toll-like receptors and 
cytokines in the spinal cord, and structural changes in 
brain areas responsible for pain perception were 
observed. Visceral hypersensitivity, pain threshold 
and many other mentioned disorders were reversed 
following microbial colonization (27). Interestingly, it 
has been observed that visceral hypersensitivity can 
be transferred from fecal microbiota of patients with 
IBS to germ free rats (28).  
These findings suggest a promise in managing 
perioperative pain in patients. In other words, 
preventive or therapeutic strategies are designed to 
ameliorate perioperative pain based on the 
interactions of gut microbiota on pain inducing 
mechanisms; these strategies though till a bit 
premature, could be a real promise in finding novel 
therapeutic approaches in pain management; both for 
acute and chronic pain. Some of these new 
perspectives are discussed in the next paragraphs (29-
36). 
Acute post-operative pain is among the most 
common and at times, intractable clinical challenges; 
with a number of therapeutic modalities being used 
for its management; however, a considerable number 
of patients suffer acute postoperative pain despite all 
these efforts; leading to both psychological burden 
and aftermath of physiologic or pathologic stress 
response due to acute pain. Though pharmaceutical 
agents are used as the main armamentarium in acute 
pain management, they lack complete efficacy in 
resolving acute pain; meanwhile, there are associated 
with a number of undesirable side effects which some 
of them are really major events. During the last 
decades, a larger number of acute pain studies have 
been involved to finding new treatments and during 
the recent years, there are studies exploring the 
considerable efficacy of modulating gut microbiota in 
alleviating acute postoperative pain (37-41). 
Implications for future studies 
Understanding the crosstalk between 
microbiota, changes in gut flora and post-operative 
pain, and recognizing the underlying mechanisms are 
novel fields of study. The potential clinical benefit of 
using probiotics in the management of acute pain is 
also of importance. Despite, differences in the nature 
of visceral and post-operative pains, it has been 
observed that some probiotics could relieve stress 
induced visceral pain in rodents. After 14 days oral 
gavage of three different probiotic strains, 
Bifidobacterium infantis 35624 decreased visceral 
pain behaviors in rats with colorectal distension (42). 
Oral Lactobacillus farciminis had similar 
antinociceptive effect in rats following colorectal 
distension and prevented stress induced 
hypersensitivity (43). A systematic review of clinical 
studies showed that specific probiotics could affect 
abdominal pain in some patients with IBS. Moreover, 
21 days supplementation with the probiotic 
Lactobacillus acidophilus NCFM increased the 
mRNA and protein expression of mu-opioid receptor 
in women with mild to moderate abdominal pain. 
Combination of Lactobacillus acidophilus NCFM 
with Bifidobacterium lactis Bi-07 decreased the 
number of days with abdominal pain significantly 
(44).  
It should be considered that the effects of 
probiotics are strain and formulation specific and 
varies from one to another. Thus, the clinical efficacy 
could not be extended to other pathophysiological 
conditions such as post-operative surgery. The safety 
and dosage of administration should be determined in 
each disease separately. Thus, further well-designed 
experimental and clinical studies are required to 
investigate the interaction between gut microbiota and 
acute post-operative pain, and the efficacy of 
probiotic supplementation. 
Conclusion 
The results of recent researches open new 
windows to management of pain through 
manipulation of gut microbiota. These results are 
wide and still need further assessment for clinical 
applicability. 
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